Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy
1. Teleflex launches Barrigel™ rectal spacer in Japan for prostate cancer treatment. 2. The product reduces rectal radiation exposure during therapy, enhancing patient safety. 3. Prostate cancer cases in Japan reached over 104,000 in 2022, 18% of all diagnoses. 4. Barrigel™ is the only NASHA rectal spacer approved for clinical use. 5. Training for physicians in Japan started recently to support product adoption.